Dialyse aktuell 2015; 19(S 01): s11-s15
DOI: 10.1055/s-0036-1571390
© Georg Thieme Verlag Stuttgart · New York

Magnesium bei chronischer Niereninsuffizienz – Was ist der aktuelle Wissensstand?

Magnesium in chronic renal insufficiency – What is the current state of knowledge?
Vincent Matthias Brandenburg
1   Klinik für Kardiologie, Universitätsklinikum Aachen, RWTH Aachen (Klinikdirektor: Univ.-Prof. Dr. Nikolaus Marx)
Nadine Kaesler
2   Klinik für Nephrologie, Universitätsklinikum Aachen, RWTH Aachen (Klinikdirektor: Univ.-Prof. Dr. Jürgen Floege)
› Institutsangaben
Weitere Informationen


25. Januar 2016 (online)

Von einem allgemeinen „Neglect“ gegenüber potenziellen gesundheitsfördernden Effekten des Magnesiums kann heute in der Nephrologie keine Rede (mehr) sein. Assoziationsstudien geben deutliche Hinweise auf solche positiven Effekte hinsichtlich z. B. protektiver Eigenschaften des Magnesiums gegenüber vaskulärer Kalzifikation. Echte Kausalität können solche Daten bisher allerdings nicht etablieren. Der Nachweis, dass eine erhöhte Magnesiumzufuhr (oral und/oder via Dialysat) klinisch relevante Endpunkte oder sogar das Überleben von CKD- oder Dialysepatienten verbessern könnte, steht noch aus. Jedoch ist die Angst vor schädlichen Effekten der üblicherweise hochnormalen oder leicht erhöhten Magnesiumwerte bei CKD- oder Dialysepatienten ebenfalls unbegründet.

The potential importance of serum magnesium levels or magnesium supplementation regarding potential health benefits is far from being settled. However, the role of magnesium in terms of benefits and harms of higher or lower serum magnesium levels attracts growing attention in research. In the past, in clinical practice, Mg was often „neglected“ by many nephrologists because it has not been adequately studied in ESRD. The role of magnesium in CKD patients needs to be investigated in more depth, additional research, well-designed and directly targeting the role of magnesium being needed, because current data, though scarce and of limited quality, are very promising for clinical endpoints, mainly cardiovascular.

  • Literatur

  • 1 Maguire ME, Cowan JA. Magnesium chemistry and biochemistry. Biometals 2002; 15: 203-210
  • 2 Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012; 5 (Suppl. 01)
  • 3 Hashizume N, Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med 1990; 29: 368-372
  • 4 Miller S, Crystal E, Garfinkle M et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005; 91: 618-623
  • 5 ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669-685
  • 6 Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-1196
  • 7 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
  • 8 Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114
  • 9 Dickinson HO, Nicolson DJ, Campbell F et al. Magnesium supplementation for the management of essential hypertension in adults. Cochrane Database Syst Rev CD 004640 2006; 3
  • 10 Salem S, Bruck H, Bahlmann FH et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012; 35: 31-39
  • 11 Van Laecke S, Marechal C, Verbeke F et al. The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. Nephrol Dial Transplant 2011; 26: 2362-2369
  • 12 Kanbay M, Yilmaz MI, Apetrii M et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012; 36: 228-237
  • 13 Hruby A, O'Donnell CJ, Jacques PF et al. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging 2014; 7: 59-69
  • 14 Qu X, Jin F, Hao Y et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PloS One 2013; 8
  • 15 Floege J. Magnesium in CKD: more than a calcification inhibitor?. J Nephrol 2015; 28: 269-277
  • 16 Massry SG. Magnesium homeostasis in patients with renal failure. Contrib Nephrol 1984; 38: 175-184
  • 17 Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012; 5 (Suppl. 01)
  • 18 Pedrozzi NE, Truttmann AC, Faraone R et al. Circulating ionized and total magnesium in end-stage kidney disease. Nephron 1998; 79: 288-292
  • 19 Wyskida K, Witkowicz J, Chudek J, Wiecek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 2012; 22: 19-26
  • 20 Ma J, Folsom AR, Melnick SL et al. Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 1995; 48: 927-940
  • 21 van den Broek FA, Beynen AC. The influence of dietary phosphorus and magnesium concentrations on the calcium content of heart and kidneys of DBA/2 and NMRI mice. Lab Anim 1998; 32: 483-491
  • 22 Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-394
  • 23 Pasch A, Farese S, Graber S et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752
  • 24 Navarro JF, Mora C, Jimenez A et al. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis 1999; 34: 43-48
  • 25 Navarro JF, Mora C, Macia M, Garcia J. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients. Perit Dial Int 1999; 19: 455-461
  • 26 de Francisco AL, Leidig M, Covic AC et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-3717
  • 27 Turgut F, Kanbay M, Metin MR et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008; 40: 1075-1082
  • 28 Mortazavi M, Moeinzadeh F, Saadatnia M et al. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 2013; 69: 309-316
  • 29 Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244
  • 30 Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181
  • 31 Fournier A, Moriniere P, Boudailliez B et al. Prevention of radiologically obvious hyperparathyroidism in dialyses patients by i.v. 1alphaOH vitamin D3 (Etalpha) in association with Mg(OH)2 as sole phosphate binder. Nieren- und Hochdruckkrankheiten 1993; 22: 39-44
  • 32 Tzanakis IP, Papadaki AN, Wei M et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008; 40: 193-201
  • 33 McIntyre CW, Pai P, Warwick G et al. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 401-409